Cellectis S.A., a clinical stage biotechnological company, develops and sells immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer in France. The company operates through two segments, Therapeutics and Plants. Its lead product candidate is UCART19, an allogeneic T-cell product candidate for the treatment of CD19 expressing hematologic malignancies, which develop in acute lymphoblastic leukemia (ALL). The company's products also comprise UCART123 for acute myeloid leukemia indications and blastic plasmacytoid dendritic cell neoplasm; UCARTCS1 for multiple myeloma (MM) indications; UCART22 for ALL; and UCART38 for T-ALL. In addition, it focuses on applying its gene-editing technologies to develop new generation plant products in the field of agricultural biotechnology. The company has strategic alliances with Pfizer Inc; Les Laboratoires Servier SAS; The University of Texas MD Anderson Cancer Center to research and develop novel cellular immunotherapies for patients suffering from various liquid tumors; and Cornell University to accelerate the development of a targeted immunotherapy for patients with acute myeloid leukemia, as well as a partnership agreement with the Wyss Institute for Biologically Inspired Engineering at Harvard University. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CLLS
Previous Symbol
CUSIPN/A
Phone33-1-81-69-16-00
Debt
Debt-to-Equity RatioN/A
Current Ratio11.23
Quick Ratio11.23
Price-To-Earnings
Trailing P/E Ratio-6.77
Forward P/E Ratio-9.09
P/E GrowthN/A
Sales & Book Value
Annual Sales$33.72 million
Price / Sales23.22
Cash FlowN/A
Price / Cash FlowN/A
Book Value$7.96 per share
Price / Book2.36
Profitability
EPS (Most Recent Fiscal Year)($2.78)
Net Income$-99,360,000.00
Net Margins-324.07%
Return on Equity-21.72%
Return on Assets-19.33%
Miscellaneous
Employees135
Outstanding Shares41,600,000
Market Cap$837.52 million
OptionableOptionable
Cellectis (NASDAQ:CLLS) Frequently Asked Questions
What is Cellectis' stock symbol?
Cellectis trades on the NASDAQ under the ticker symbol "CLLS."
How were Cellectis' earnings last quarter?
Cellectis SA (NASDAQ:CLLS) announced its quarterly earnings results on Wednesday, August, 1st. The biotechnology company reported ($0.17) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.62) by $0.45. The biotechnology company earned $8.34 million during the quarter, compared to the consensus estimate of $9.43 million. Cellectis had a negative net margin of 324.07% and a negative return on equity of 21.72%. View Cellectis' Earnings History.
When is Cellectis' next earnings date?
What price target have analysts set for CLLS?
4 analysts have issued 12-month price targets for Cellectis' shares. Their forecasts range from $44.00 to $73.00. On average, they expect Cellectis' share price to reach $55.6667 in the next twelve months. This suggests a possible upside of 196.7% from the stock's current price. View Analyst Price Targets for Cellectis.
What is the consensus analysts' recommendation for Cellectis?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cellectis in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cellectis.
Has Cellectis been receiving favorable news coverage?
Media headlines about CLLS stock have been trending somewhat positive this week, according to InfoTrie Sentiment Analysis. The research group rates the sentiment of media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Cellectis earned a coverage optimism score of 1.8 on InfoTrie's scale. They also gave press coverage about the biotechnology company a news buzz of 3.0 out of 10, indicating that recent media coverage is unlikely to have an effect on the stock's share price in the next several days.
Who are some of Cellectis' key competitors?
Some companies that are related to Cellectis include argenx (ARGX), Allogene Therapeutics (ALLO), Repligen (RGEN), China Biologic Products (CBPO), Halozyme Therapeutics (HALO), Acceleron Pharma (XLRN), Denali Therapeutics (DNLI), Atara Biotherapeutics (ATRA), Crispr Therapeutics (CRSP), Aerie Pharmaceuticals (AERI), Regenxbio (RGNX), Rubius Therapeutics (RUBY), Spark Therapeutics (ONCE), Editas Medicine (EDIT) and Orchard Therapeutics (ORTX).
Who are Cellectis' key executives?
Cellectis' management team includes the folowing people:
- Dr. André Choulika, Co-Founder, Chairman & CEO (Age 53)
- Dr. David J. D. Sourdive, Co-Founder, Exec. VP of Technical Operations & Director (Age 51)
- Mr. Eric Dutang, Chief Financial Officer (Age 44)
- Ms. Elsy Boglioli, Chief Operating Officer (Age 36)
- Mr. Jean Charles Epinat, Chief Technological Officer
When did Cellectis IPO?
(CLLS) raised $129 million in an initial public offering (IPO) on Wednesday, March 25th 2015. The company issued 3,500,000 shares at a price of $36.83 per share. BofA Merrill Lynch, Jefferies and Piper Jaffray acted as the underwriters for the IPO and Oppenheimer was co-manager.
Who are Cellectis' major shareholders?
Cellectis' stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (1.21%), Morgan Stanley (1.16%), Sphera Funds Management LTD. (1.08%), Credit Suisse AG (1.01%), ARK Investment Management LLC (0.95%) and Tekla Capital Management LLC (0.67%).
Which institutional investors are selling Cellectis stock?
CLLS stock was sold by a variety of institutional investors in the last quarter, including Laurion Capital Management LP, Tekla Capital Management LLC, Axiom International Investors LLC DE, Wells Fargo & Company MN, Vident Investment Advisory LLC and Oppenheimer & Co. Inc..
Which institutional investors are buying Cellectis stock?
CLLS stock was acquired by a variety of institutional investors in the last quarter, including Macquarie Group Ltd., ARK Investment Management LLC, Opaleye Management Inc., Morgan Stanley, Sphera Funds Management LTD., Point72 Asset Management L.P., First Light Asset Management LLC and BlackRock Inc..
How do I buy shares of Cellectis?
Shares of CLLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cellectis' stock price today?
One share of CLLS stock can currently be purchased for approximately $18.76.
How big of a company is Cellectis?
Cellectis has a market capitalization of $837.52 million and generates $33.72 million in revenue each year. The biotechnology company earns $-99,360,000.00 in net income (profit) each year or ($2.78) on an earnings per share basis. Cellectis employs 135 workers across the globe.
What is Cellectis' official website?
How can I contact Cellectis?
Cellectis' mailing address is 8 RUE DE LA CROIX JARRY, PARIS I0, 75013. The biotechnology company can be reached via phone at 33-1-81-69-16-00 or via email at [email protected]
MarketBeat Community Rating for Cellectis (NASDAQ CLLS)
MarketBeat's community ratings are surveys of what our community members think about Cellectis and other stocks. Vote "Outperform" if you believe CLLS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CLLS will underperform the S&P 500 over the long term. You may vote once every thirty days.
